Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population

Pathology

Volumn 38, Issue 5, 2006, Pages 442-444

  Zaatari, Ghazi S ^a   Otrock, Zaher K ^a   Sabbagh, Amira S ^a   Mahfouz, Rami A R ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Factor V; HR2 haplotype; Lebanese population; Polymorphism; Prevalence

Indexed keywords

BLOOD CLOTTING FACTOR 5;

ADOLESCENT; ADULT; AGED; ARTICLE; DNA EXTRACTION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYBRIDIZATION; LEBANON; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; REGISTER; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; LEBANON; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; VENOUS THROMBOSIS;

EID: 33749159656     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020600922934     Document Type: Article

References (24)

1. Rosing J, Tans G, Govers-Riemslag JW, et al. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-83.
2. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
3. Bertina RM, Reitsma PH, Rosendaal FR, et al. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
4. Lunghi B, Iacoviello L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
5. Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R 506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
6. Castoldi E, Rosing J, Girelli D, et al. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000; 83: 362-5.
7. Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81: 193-7.
8. Faioni EM, Franchi F, Bucciarelli P, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94: 3062-6.
9. de Visser MC, Guasch JF, Kamphuisen PW, et al. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83: 577-82.
10. Luddington R, Jackson A, Pannerselvam S, et al. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000; 83: 204-8.
11. Akar N, Yilmaz E, Akar E, et al. Factor V (His 1299 Arg) in young Turkish patients with cerebral infarct. Haemostasis 2000; 30: 118-22.
12. Benson JM, Ellingsen D, El-Jamil M, et al. Factor V Leiden and factor V R2 allele: high-throughput analysis and association with venous thromboembolism. Thromb Haemost 2001; 86: 1188-92.
13. Pecheniuk NM, Morris CP, Walsh TP, et al. The factor V HR2 haplotype: prevalence and association of the A4070G and A6755G polymorphisms. Blood Coagul Fibrinolysis 2001; 12: 201-6.
14. Kostka H, Schwarz T, Schellong S, et al. Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis. Blood Coagul Fibrinolysis 2003; 14: 49-56.
15. Herrmann FH, Salazar-Sanchez L, Jimenez-Arce G, et al. High prevalence of FVHR2 polymorphism in Costarician Indians who have no FVL. Thromb Haemost 2001; 85: 1120-1.
16. Jadaon MM, Dashti AA. HR2 haplotype in Arab population and patients with venous thrombosis in Kuwait. J Thromb Haemost 2005; 3: 1467-71.
17. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-44.
18. Margaglione M, Bossone A, Coalizzo D, et al. FV HR2 haplotype as additional inherited risk factor for deep venous thrombosis in individuals with a high-risk profile. Thromb Haemost 2002; 87: 32-6.
19. Castaman G, Lunghi B, Missiaglia E, et al. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V. Br J Haematol 1997; 99: 257-61.
20. Pittman DD, Tomkinson KN, Kaufman RJ. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 1994; 269: 17329-37.
21. Faioni EM, Castaman G, Asti D, et al. Association of factor V deficiency with factor V HR2. Haematologica 2004; 89: 195-200.
22. Doggen CJ, de Visser MC, Vos HL, et al. The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost 2000; 84: 815-8.
23. Lecumberri R, Ceberio I, Montes R, et al. Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease. Haematologica 2003; 88: 236-7.
24. Yanqing H, Fangping C, Qinzhi X, et al. No association between thrombosis and factor V gene polymorphisms in Chinese Han population. Thromb Haemost 2003; 89: 446-51.